Advances in Combination Therapy of Immune Checkpoint Inhibitors for Lung Cancer.
10.3779/j.issn.1009-3419.2020.02.05
- Author:
Hanfei GUO
1
;
Rilan BAI
1
;
Jiuwei CUI
1
Author Information
1. Cancer Center, The First Bethune Hospital of Jilin University, Changchun 130021, China.
- Publication Type:Journal Article
- Keywords:
Combination therapy;
Immune checkpoint inhibitors;
Lung neoplasms
- From:
Chinese Journal of Lung Cancer
2020;23(2):101-110
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors (ICIs) therapy is the most commonly used immunotherapy regimen at present. It has been approved for clinical treatment of melanoma, kidney cancer, head and neck cancer, bladder cancer and other tumors. It has made a breakthrough in the treatment of lung cancer and become a new pillar of comprehensive treatment of lung cancer. However, ICIs alone is less effective in non-selective patients, and combination therapy has become a hot topic of exploration. This article focuses on the development of combined immune checkpoint inhibitors and describes how immunotherapy can be used to treat early stage cancer.
